Literature DB >> 6646495

Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia.

T Nishikawa, M Takashima, M Toru.   

Abstract

[3H]Kainic acid binding sites were measured post mortem in the putamen and prefrontal cortex areas from 10 control subjects and 12 schizophrenic patients. A 25-50% increase in [3H]kainic acid binding was observed in the medial frontal (Brodmann areas 9, 10 and 46) and eye-movement areas (8), but not in the other regions of schizophrenic brains. No significant correlation between the binding and either age at death, storage of the brains, duration of illness or neuroleptics-free period was observed. These findings suggest that a dysfunction of cortical excitatory amino acidergic transmission may be involved in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6646495     DOI: 10.1016/0304-3940(83)90046-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 3.  Imaging genomics and response to treatment with antipsychotics in schizophrenia.

Authors:  Giuseppe Blasi; Alessandro Bertolino
Journal:  NeuroRx       Date:  2006-01

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Proceedings of the British Pharmacological Society. Ireland, 6th-8th July, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 6.  Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.

Authors:  Amr Ellaithy; Jason Younkin; Javier González-Maeso; Diomedes E Logothetis
Journal:  Trends Neurosci       Date:  2015-07-04       Impact factor: 13.837

7.  Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics.

Authors:  L J Garey; K A Von Bussmann; S R Hirsch
Journal:  Exp Brain Res       Date:  2006-02-28       Impact factor: 1.972

8.  Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.

Authors:  B Glenthøj
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics.

Authors:  Y Kiuchi; T Kobayashi; J Takeuchi; H Shimizu; H Ogata; M Toru
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

10.  An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia.

Authors:  Junko Sato; Dai Shimazu; Naoki Yamamoto; Toru Nishikawa
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.